<DOC>
	<DOCNO>NCT01297062</DOCNO>
	<brief_summary>Compare effect exenatide ( therapeutic supratherapeutic concentration ) , moxifloxacin placebo QT interval .</brief_summary>
	<brief_title>A Safety Study Assess Effects Therapeutic Supratherapeutic Exenatide Concentrations QT Interval Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Is overtly healthy , determined medical history physical examination Has body mass index ( BMI ) 25 35 kg/m2 Has fasting serum glucose &lt; 110 mg/dL Has clinically significant blood pressure heart rate reading judge investigator study start Has electrocardiogram ( ECG ) result judge clinically significant investigator study start Has clinically significant medical condition could potentially affect study participation and/or personal wellbeing Has abnormality 12lead ECG , opinion investigator , increase risk participate study , Bazett 's correct QT ( QTcB ) interval &gt; 450 ms. Family history sudden death Personal history unexplained syncope within last year , family history Long QT Syndrome , significant active cardiac disease , symptom angina pectoris transient ischemic attack within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>QT interval</keyword>
</DOC>